PDS Biotechnology Corporation(PDSB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PDSB PDS Biotechnology Corporation

交易中 10-16 14:34:10 EDT

1.10

-0.20

-15.38%

最高1.26	最低1.10	成交量562.23万
今开1.25	昨收1.30	日振幅12.31%
总市值1.16亿	流通市值6,386万	总股本1.05亿
成交额651.60万	换手率9.68%	流通股本5,806万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PDSB","market":"US","secType":"STK","nameCN":"PDS Biotechnology Corporation","latestPrice":1.1,"timestamp":1792175633276,"preClose":1.3,"halted":0,"volume":5622319,"delay":0,"changeRate":-0.1538461538461538,"floatShares":58056400,"shares":105005400,"eps":-0.640141,"marketStatus":"交易中","change":-0.2,"latestTime":"10-16 14:34:10 EDT","open":1.25,"high":1.26,"low":1.1,"amount":6516024.8368192,"amplitude":0.123077,"askPrice":1.11,"askSize":2926,"bidPrice":1.1,"bidSize":10675,"shortable":0,"etf":0,"ttmEps":-0.640141,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1792180800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1443672000000,"exchange":"NASDAQ","adjPreClose":1.3,"preHourTrading":{"tag":"盘前","latestPrice":1.2401,"preClose":1.3,"latestTime":"09:29 EDT","volume":145911,"amount":184232.4084405,"timestamp":1792157374444,"change":-0.0599,"changeRate":-0.046077,"amplitude":0.072538},"postHourTrading":{"tag":"盘后","latestPrice":1.3423,"preClose":1.3,"latestTime":"19:58 EDT","volume":65928,"amount":86957.3833,"timestamp":1792108681607,"change":0.0423,"changeRate":0.032538,"amplitude":0.046154},"volumeRatio":0.530207,"impliedVol":2.1445,"impliedVolPercentile":0.9721},"requestUrl":"/m/hq/s/PDSB","defaultTab":"news","newsList":[{"id":"1196247798","title":"PDS生物技术宣布Versatile-002二期临床试验结果发表于《JAMA肿瘤学》：PDS0101联合帕博利珠单抗治疗HPV16阳性复发/转移性头颈癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1196247798","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196247798?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:01","pubTimestamp":1790078496,"startTime":"0","endTime":"0","summary":"PDS生物技术公司今日宣布，其备受关注的Versatile-002二期临床试验结果已正式发表于国际顶级医学期刊《JAMA肿瘤学》。这项研究聚焦于PDS0101与帕博利珠单抗的联合疗法，针对的是HPV16阳性复发性和/或转移性（R/M）头颈癌患者。值得注意的是，此次发表不仅验证了联合用药方案的安全性与耐受性，更展现了其在特定患者群体中令人鼓舞的抗肿瘤活性。PDS生物技术公司正积极推进该候选药物的临床开发进程，为全球头颈癌患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PDSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114267783","title":"PDS生物技术宣布完成至多2230万美元的PIPE融资首轮交割，并任命Patrick Soon-Shiong博士为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1114267783","media":"美股速递","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114267783?lang=zh_cn&edition=full","pubTime":"2026-09-14 22:31","pubTimestamp":1789396270,"startTime":"0","endTime":"0","summary":"PDS生物技术公司今日正式宣布，已成功完成高达2230万美元的PIPE融资的首次交割。与此同时，该公司还披露了一项重大人事变动——任命Patrick Soon-Shiong博士加入其董事会。PDS生物技术公司作为一家专注于开发癌症免疫疗法的临床阶段生物制药企业，此次融资的成功交割，标志着公司在推进其创新疗法研发管线的道路上迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PDSB","IBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190125233","title":"PDS生物技术宣布获得最高达2255万美元融资，由Nantworks创始人黄馨祥博士领投","url":"https://stock-news.laohu8.com/highlight/detail?id=1190125233","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190125233?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:31","pubTimestamp":1788870674,"startTime":"0","endTime":"0","summary":"PDS生物技术公司今日宣布，已达成一项总额最高可达2255万美元的融资协议。此轮融资由Nantworks创始人黄馨祥博士领衔主导。据悉，此项融资安排彰显了市场对PDS生物技术平台及其在免疫疗法领域创新潜力的高度认可。黄馨祥博士作为生物医药领域的知名投资人及企业家，其领投举动无疑为该公司注入了强劲的信心背书。PDS生物技术管理层对此次融资表示高度期待，并承诺将利用新获资金加速关键项目的推进，以期早日为患者带来创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PDSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195092528","title":"PDS生物技术公司宣布解除Stephan Toutain首席运营官职务，自2026年8月21日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1195092528","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195092528?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:11","pubTimestamp":1787688689,"startTime":"0","endTime":"0","summary":"PDS生物技术公司（PDS Biotechnology Corporation）近日向美国证券交易委员会提交的文件显示，公司已正式解除Stephan Toutain的首席运营官职务。这一人事变动将于2026年8月21日正式生效。\n据披露文件确认，此次管理层调整已尘埃落定。Toutain的离任，标志着该公司在运营领导层方面迎来新的变动节点。\n值得关注的是，这一决定正值公司发展的关键时期。PDS生物技术作为一家专注于免疫疗法研发的创新型企业，其管理团队的调整无疑将引发市场各方的密切关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDSB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190128204","title":"PDS Biotechnology宣布裁员计划，优化资源配置以聚焦战略重点","url":"https://stock-news.laohu8.com/highlight/detail?id=1190128204","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190128204?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:11","pubTimestamp":1787688669,"startTime":"0","endTime":"0","summary":"8月6日，PDS Biotechnology Corporation（PDSB）通过美国证券交易委员会（SEC）文件披露，公司已正式批准一项人员精简方案。此举旨在调整运营成本结构，使其与既定战略优先事项保持一致。这家生物技术企业正通过削减人力开支，来应对当前阶段的资金配置需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PDSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195451064","title":"PDS Biotechnology宣布CFO Lars Boesgaard将于9月12日卸任","url":"https://stock-news.laohu8.com/highlight/detail?id=1195451064","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195451064?lang=zh_cn&edition=full","pubTime":"2026-08-20 04:56","pubTimestamp":1787172970,"startTime":"0","endTime":"0","summary":"PDS Biotechnology Corporation（纳斯达克代码：PDSB）今日向美国证券交易委员会（SEC）提交的文件显示，公司首席财务官（CFO）、首席财务主管及首席会计主管Lars Boesgaard将于9月12日正式卸任。\n这一高层人事变动在SEC文件中得以披露，标志着该公司财务管理层将迎来新的调整期。Boesgaard的离职生效日期恰逢9月中旬，为公司留出了一定的过渡与交接时间。\nPDS Biotechnology作为一家专注于免疫疗法研发的生物技术企业，此番核心财务高管更迭备受市场关注。截至目前，公司尚未公布继任者的具体人选或相关过渡安排，外界或将继续关注其后续动向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDSB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133631174","title":"PDS生物技术公司宣布战略重组：聚焦PDS0301进军转移性结直肠癌，并为PDS0101制定合作策略","url":"https://stock-news.laohu8.com/highlight/detail?id=1133631174","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133631174?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:26","pubTimestamp":1786451201,"startTime":"0","endTime":"0","summary":"PDS生物技术公司（PDS Biotechnology Corporation）近日正式对外宣布一项重大战略调整。此次重组表明，公司将把研发重心全力倾斜至其核心候选药物PDS0301之上，目标直指转移性结直肠癌（mCRC）这一严峻的适应症领域。与此同时，针对另一款关键在研产品PDS0101，管理层也已明确规划出一条全新的合作路径，冀望通过外部联盟来加速其临床开发与商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDSB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116772975","title":"PDS Biotechnology宣布终止对PDS0101三期Versatile-003试验的内部投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1116772975","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116772975?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:26","pubTimestamp":1786451169,"startTime":"0","endTime":"0","summary":"PDS Biotechnology Corporation（代码：PDSB）披露，已决定停止对PDS0101三期Versatile-003临床试验的内部资金投入。这一战略调整意味着，这家生物科技公司不再继续为该项关键试验提供内部资本支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDSB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116114948","title":"PDS Biotechnology Corporation公布NCI主导的转移性结直肠癌二期临床试验第一阶段积极中期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1116114948","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116114948?lang=zh_cn&edition=full","pubTime":"2026-04-15 20:46","pubTimestamp":1776257183,"startTime":"0","endTime":"0","summary":"PDS Biotechnology Corporation宣布，其PDS01ADC在由国家癌症研究所（NCI）主导的转移性结直肠癌（MCRC）二期临床试验第一阶段的中期研究数据已正式发表。此次公布的数据显示积极的临床效果，为后续治疗方案的推进提供了重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDSB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pdsbiotech.com","stockEarnings":[{"period":"1week","weight":0.2745},{"period":"1month","weight":1.2211},{"period":"3month","weight":0.7689},{"period":"6month","weight":-0.0076},{"period":"1year","weight":0.3305},{"period":"ytd","weight":0.6888}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.019},{"period":"3month","weight":0.0383},{"period":"6month","weight":0.0868},{"period":"1year","weight":0.1603},{"period":"ytd","weight":0.1318}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PDS Biotechnology Corporation于2009年1月22日根据特拉华州法律成立。该公司是一家临床阶段的生物技术公司，专注于发现，开发和寻求商业化的新颖的以医院为基础的治疗方案，能够改变治疗模式和危及生命的管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.025289},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.061437},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.164348},{"month":4,"riseRate":0.454545,"avgChangeRate":0.079515},{"month":5,"riseRate":0.545455,"avgChangeRate":0.158069},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.000335},{"month":7,"riseRate":0.545455,"avgChangeRate":0.070482},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.072928},{"month":9,"riseRate":0.363636,"avgChangeRate":0.156782},{"month":10,"riseRate":0.363636,"avgChangeRate":0.048649},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.002317},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.051726}],"exchange":"NASDAQ","name":"PDS Biotechnology Corporation","nameEN":"PDS Biotechnology Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PDS Biotechnology Corporation(PDSB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PDS Biotechnology Corporation(PDSB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PDS Biotechnology Corporation,PDSB,PDS Biotechnology Corporation股票,PDS Biotechnology Corporation股票老虎,PDS Biotechnology Corporation股票老虎国际,PDS Biotechnology Corporation行情,PDS Biotechnology Corporation股票行情,PDS Biotechnology Corporation股价,PDS Biotechnology Corporation股市,PDS Biotechnology Corporation股票价格,PDS Biotechnology Corporation股票交易,PDS Biotechnology Corporation股票购买,PDS Biotechnology Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PDS Biotechnology Corporation(PDSB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PDS Biotechnology Corporation(PDSB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}